Miravant SnET2 NDA Filing Target Is Q1 2004; Funds Could Run Out Mid-Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Miravant is planning to submit an NDA for its SnET2 PhotoPoint photodynamic therapy for wet age-related macular degeneration in the first quarter of 2004, according to a Nov. 14 quarterly report filed with the Securities & Exchange Commission.
You may also be interested in...
Miravant eyes priority review for SnET2
Miravant is requesting a priority review for its SnET2 (rostaporfin) for treatment of wet age-related macular degeneration with any classic component. The March 31 submission meets the firm's previously announced first-quarter 2004 filing target (1Pharmaceutical Approvals Monthly Dec. 1, 2003, p. 7). The NDA is based on subset analyses of Phase III studies; Pharmacia opted out of its development agreement in January 2002 when the photodynamic therapy did not meet the primary endpoint in the overall study population. A Premarket Approval Application for the ophthalmic laser that activates rostaporfin was submitted in conjunction with the NDA...